Tamara Balsiger

Tamara Balsiger

Auto-generated profile, based on publicly available information

Tamara Balsiger

Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2025 in Phytochemistry
Verified
Journal Article
Open access
RHRuzhe Han
Ruzhe Han
TBTamara Balsiger
Tamara Balsiger
MDMaciej Dobrzyński
Maciej Dobrzyński
LDLara Dürr
Lara Dürr
THTanja Hell
Tanja Hell
EGEliane Garo
Eliane Garo
Melanoma, a highly aggressive form of skin cancer, is primarily driven by two key oncogenic signaling pathways: MAPK/ERK and PI3K/AKT. In a discovery program aiming to identify natural products that inhibit one or both pathways, an in-house library of 2'576 plant extracts was screened using a high-content screening assay with melanoma cells expressing ERK/AKT activity biosensors to quantify inhibition at the single-cell level. The ethyl acetate extract from the leaves of Mammea americana was found to inhibit both pathways in the patient-derived cell line MM121224 and was selected for HPLC-based activity profiling. Scale-up isolation of the compounds eluting in the active window of the chromatogram afforded ten previously undescribed betulinic acid analogues (1-10), along with nine known coumarins (11-19). The isolated compounds were individually evaluated for their inhibitory activity on ERK and AKT in MM121224 cells. Interestingly, none of the betulinic acid derivatives 1-10 showed activity in the assay. In contrast, the isolated coumarins were shown to inhibit both pathways, with the most potent theraphin B (11) exhibiting an IC50 value of 37.0 ± 0.4 μM against the AKT pathway, while also demonstrating weaker activity against the ERK pathway.

6 July 2026 in Planta Medica
Verified
Journal Article
Closed access
TBTamara Balsiger
Tamara Balsiger
MRMalik Rakhmanov
Malik Rakhmanov
APAlessandro Prescimone
Alessandro Prescimone
AKAnnalena Kaiser
Annalena Kaiser
KHKim-Dung Huynh
Kim-Dung Huynh
EGEliane Garo
Eliane Garo
Forgetting and memory formation are 2 distinct processes, both essential for the survival of humans and other animals. The protein Musashi2 (MSI2) was recently discovered as a key regulator of forgetting in the model organism Caenorhabditis elegans, making it an attractive therapeutic target for drug discovery and development. Here, we report a fluorescence polarization assay-based screening campaign aimed at identifying MSI2 inhibitors from 2,844 plant extracts. The dichloromethane extract of the aerial parts of Huperzia serrata, a plant traditionally used in Chinese medicine for the treatment of memory dysfunction, was identified as a hit and subsequently subjected to HPLC-based activity profiling. Scale-up isolation identified fatty acids, namely linoleic acid (11) and palmitoleic acid (12), both eluting within the main active window. As other fractions also seem to display activity, although weaker, their minor constituents were also investigated, revealing 1 new serratane triterpenoid (1) and 7 known serratene triterpenoids 2-8, their biosynthetic precursor α-onocerin (9), as well as an abietane diterpene (10). The absolute configuration of compound 1 was established by X-ray crystallography. All isolated compounds were evaluated for their activity, revealing that linoleic acid (11) and palmitoleic acid (12) inhibited MSI2 with IC50 values of 14.6 and 23.1 µM, respectively, while compound 10 only showed moderate activity (IC50 of 34.4 µM).